Editor: What To Know
- We are well-positioned to further accelerate the market adoption of OMNI® in the coming months as we roll out our next generation product and to execute a best-in-class commercial launch for TearCare®.
- Paul Badawi, Founder and CEO of Sight Sciences commented, “We are excited to launch these two innovative products that can transform the way surgeons and eye care professionals target the underlying cause of two of the world’s most prevalent eye diseases.
- As we penetrate and expand these two substantial, rapidly growing markets over the coming years, our goal is to be amongst the top performing companies in ophthalmology as well as MedTech more broadly,”.
Sight Sciences, Inc. today announced the official commercial launch of TearCare ® as well as the introduction of their aesthetically and ergonomically enhanced OMNI ® Surgical System (initially launched in February 2018).
Sight Sciences is a growth-stage medical device company transforming the two fastest growing segments in ophthalmology and optometry – dry eye and glaucoma.
Paul Badawi, Founder and CEO of Sight Sciences commented, “We are excited to launch these two innovative products that can transform the way surgeons and eye care professionals target the underlying cause of two of the world’s most prevalent eye diseases.: He added, “We have been thrilled with the market receptivity to our first-generation OMNI® system, which we have been selling since early 2018 through our world class surgical commercial team built from the ground up by Shawn O’Neil, our Chief Commercial Officer. Given Shawn’s long history of developing and leading high-performance teams in both surgical devices and vision care, we are excited to replicate this success with the commercial launch of TearCare®,” said
“First and foremost, our surgical and vision care teams fully appreciate the clinical value of the groundbreaking products we are bringing to our MD and OD customer bases. We have built a highly robust and pedigreed commercial force comprised of two discrete, specialized sales and marketing teams for both the Dry Eye (TearCare®) and MIGS (OMNI®) practice areas. We are well-positioned to further accelerate the market adoption of OMNI® in the coming months as we roll out our next generation product and to execute a best-in-class commercial launch for TearCare®. As we penetrate and expand these two substantial, rapidly growing markets over the coming years, our goal is to be amongst the top performing companies in ophthalmology as well as MedTech more broadly,” said Shawn O’Neil, Chief Commercial Officer of Sight Sciences.
The rollout of the new devices will include product demonstrations, presentations and events at a number of the eye care industry’s upcoming premier shows, including:
- Vision Source Exchange, held May 1-4 in Tampa, FL, at booth #1129.
- American Society of Cataract and Refractive Surgery and American Society of Ophthalmic Administrators (ASCRS/ASOA) annual meetings, held May 3-7 in San Diego, CA, at booth #1307.
- American Optometric Association (AOA) annual meeting, held June 19-23 in St. Louis, MO, at booth #1215.
